Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25145240 | 0.82 | LMNA (0.33) | F2KMT2AMAPTHSD17B10KDM4E | |
| SCHEMBL25145226 | 0.81 | ADORA3 (0.35) | KMT2AMAPTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL21547858 | 0.78 | LMNA (0.34) | HSD17B10ALDH1A1LMNA | |
| SCHEMBL21538913 | 0.76 | F2 (0.33) | F2KMT2AMAPTHSD17B10 | |
| SCHEMBL21366197 | 0.75 | KMT2A (0.39) | F2KMT2AMAPTHSD17B10ALDH1A1 | |
| SCHEMBL21366308 | 0.73 | HSD17B10 (0.35) | F2KMT2AMAPTHSD17B10KDM4E | |
| SCHEMBL21366409 | 0.71 | CES1 (0.32) | HSD17B10KDM4EALDH1A1RAF1 | |
| SCHEMBL21366406 | 0.71 | CES1 (0.34) | KMT2AMAPTKDM4EALDH1A1LMNA | |
| SCHEMBL25144923 | 0.70 | NPSR1 (0.32) | F2MAPTHSD17B10KDM4EALDH1A1 | |
| SCHEMBL21366414 | 0.70 | NPSR1 (0.39) | F2KMT2AMAPTHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190307731-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190284149-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307731-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | AHR, ARNT, NR1H4 | F2 4310/4885KMT2A 1490/4885MAPT 4875/4885 |
| US-20190284149-A1 | ARYL HYDROCARBON RECEPTOR MODULATOR | AHR, ARNT, NR1H4 | F2 4315/4885KMT2A 1445/4885MAPT 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.